Clinical efficacy of Shirishavaleha on Tamaka Bronchial Asthma
Phase 2
Completed
- Conditions
- Health Condition 1: null- Patients having classical signs and symptoms of Tamaka Shwasa (Bronchial Asthma)
- Registration Number
- CTRI/2016/03/006695
- Lead Sponsor
- IPGT RA JAMNAGAR
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Mild persistent cases of Bronchial Asthma withdaytime symptoms 3-6/week and nocturnal symptoms with 3-4/month.
Moderate persistence cases with daytime symptoms daily and nocturnal symptoms with one or more than one week but not more than 2 weeks.
Exclusion Criteria
Known patients of diabetes,
Dyspnoea resulting from cardiac origin, anaemia,
Age above 60 years and below 20 years,
Patients suffering from tuberculosis, malignancy and other chronic debilitating diseases, HIV positive cases,
Pregnant and lactating mothers
Patients who depend on regular use of inhalers,
Patients suffering with other types of Shwasa explained in AYurveda classics like i.e. Maha, Urdha, Chhinna Shwasa will be excluded from the study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method It is expected that the trial drugs will exert a <br/ ><br>significant action on Signs and Symptoms of <br/ ><br>Tamaka Shwasa. Improvement in AEC and other <br/ ><br>haematological <br/ ><br>(TLC, DLC, Hb, AEC), Peak Expiratory Flow <br/ ><br>Rate and Breath Holding Time.Timepoint: A special scoring pattern will be followed for <br/ ><br>assessing improvement in signs and symptoms <br/ ><br>Routine urine and haematological investigations <br/ ><br>will be carried out to exclude other pathology <br/ ><br>Special investigations BHT and PEFR will be <br/ ><br>carried out for before and after treatment for <br/ ><br>assessment
- Secondary Outcome Measures
Name Time Method By providing better effect on Tamaka Shwasa, the drug will effect psychosomatic level of the enrolled patients, enhance quality of life and will contribute in reducing disability adjusted life years. <br/ ><br>Overall improvement in the disease condition, Quality of Life of the diseased. <br/ ><br>Based on the observations, the trial drug may be <br/ ><br>recommended to be added into the Essential Drugs List of Ministry of AYUSH, New DelhiTimepoint: 18 months of trial